Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, seven have assigned a buy recommendation and one has issued […]
Amalgamated Bank raised its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 5.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,172 shares of the company’s stock after acquiring an additional 772 shares during the period. Amalgamated Bank’s […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its price target increased by research analysts at The Goldman Sachs Group from $91.00 to $102.00 in a research report issued on Tuesday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 53.52% from […]